Clinical trials: sponsored by Chinese PLA General Hospital
Pulmonary Disease
Influence of Early Standing Training on ICU Patients
Influence of early standing training on ICU patients
- Trial name
- NCT04460391
- Testing
- Intensive rehabilitation
- Volunteers
- 50 people
- Sponsor
- Chinese PLA General Hospital
Pulmonary Disease
Effects of Standing at Different Angles on Transpulmonary Pressure
Effects of standing at different angles on transpulmonary pressure
- Trial name
- NCT04451421
- Testing
- Change of standing Angle
- Volunteers
- 50 people
- Sponsor
- Chinese PLA General Hospital
Evaluate the Safety and Effectiveness of Mesenchymal Stem Cell Conditioned Medium-derived Pleiotropic Factor in Treating Donor Sites
Mesenchymal Stem Cell-derived Pleiotropic Factor in the Treatment of Donor Sites
Skin grafting is a standard treatment for deep wounds, but care of the donor site after transplantation is very important. The means of accelerating wound healing can increase overall patient satisfaction.
- Trial name
- NCT04234750
- Testing
- mesenchymal stem cell conditioned medium-derived pleiotropic factor
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese PLA General Hospital
Mesenchymal Stem Cell-derived Pleiotropic Factor in Treating Residual Burn Wound
Mesenchymal Stem Cell Conditioned Medium-derived Pleiotropic Factor in Treating Residual Burn Wound
Treatment of extensive deep burn residual wounds is a common problem in burn plastic surgery. Due to bacterial invasion, excessive maturation of granulation tissue, poor abrasion resistance of new epithelium, and coexistence of…
- Trial name
- NCT04235296
- Testing
- epidermal growth factor, mesenchymal stem cell conditioned medium-derived pleiotropic factor
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Mesenchymal Stem Cell-derived Bioactivator for Treating Chronic Wounds
Mesenchymal Stem Cell-derived Pleiotropic Factor in Treating Non-healing Wounds
Chronic wounds do not heal for prolonged periods of time with the significant financial burden on the healthcare system. It has become increasingly essential to improve our clinical treatments.
- Trial name
- NCT04235868
- Testing
- Stem cell-derived derived pleiotropic factor, fibroblast growth factor
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Gastric Cancer
Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer
For locally advanced gastric cance, neoadjuvant chemotherapy can increase the resectability of tumor, and finally improve the long-term survival.
- Trial name
- NCT04367025
- Testing
- Camrelizumab, Oxaliplatin, S1
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Chinese PLA General Hospital
Hepatocellular Carcinoma
To Compare the Efficacy of Microwave Ablation and Laparoscopic Hepatectomy for Hepatocellular Carcinoma
The study was a prospective multicenter cohort control study, which was divided into 1:1 groups to compare the clinical efficacy of percutaneous microwave ablation and laparoscopic hepatocellular carcinoma resection (tumor…
- Trial name
- NCT04365751
- Testing
- Percutaneous microwave ablation, Laparoscopic hepatectomy
- Where
- China
- Volunteers
- 1,134 people
- Sponsor
- Chinese PLA General Hospital
Diaphragm Ultrasound, Intensive Care Unit
The Value of Diaphragmatic Ultrasound in Non-invasive Oxygen Therapy
In this study, a single-center, prospective, observational study was adopted to set the cut-off values of diaphragmatic ultrasound results and arterial blood gas results，with the choice of non-invasive oxygen therapy as the gold…
- Trial name
- NCT04355559
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Chinese PLA General Hospital
Non Hodgkin Lymphoma
Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor
This is a Phase I/II clinical trial for patients with r/r Non-Hodgkin's Lymphoma relapsed after chimeric antigen receptor T cells infusion.
- Trial name
- NCT04337606
- Testing
- Chidamide, Decitabine, Camrelizumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
COPD, Hypercapnic Respiratory Failure
HFNC vs NPPV After Early Extubation for Patients With COPD
High-flow nasal cannula oxygen therapy(HFNC) has proved no significant difference compared with noninvasive positive pressure ventilation (NPPV) in preventing postextubation respiratory failure and reintubation in patients with…
- Trial name
- NCT04156139
- Testing
- HFNC, NPPV
- Where
- China
- Volunteers
- 502 people
- Sponsor
- Chinese PLA General Hospital
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer
The purpose of this study was to evaluate the efficacy and safety of simple local ablation, local ablation combined with apatinib, local ablation combined with apatinib and PD-1 antibody SHR-1210 for the treatment of advanced…
- Trial name
- NCT04204577
- Testing
- Apatinib Mesylate
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Chinese PLA General Hospital
Liver Cancer, Pancreatic Cancer
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
- Conditions
- Liver Cancer, Pancreatic Cancer, Brain Tumor, Breast Cancer
- Trial name
- NCT02541370
- Testing
- anti-CD133-CAR vector-transduced T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese PLA General Hospital
Kidney Failure,Chronic
Safety, Effectiveness and Manipulability Evaluation of a Domestic PD Machine
This study is a randomized, multi-center，crossover study of a domestic FM peritoneal dialysis machine and Baxter HOMECHOICE.It aims to verify safety, effectiveness and manipulability of a domestic peritoneal dialysis machine.
- Trial name
- NCT02525497
- Testing
- FM peritoneal dialysis machine, HOMECHOICE peritoneal dialysis machine
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Chinese PLA General Hospital
Advanced Gastric Cancer
Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer
This is a Phase I/II , Open-label , Investigator-initiated Trail of Camrelizumab (an Anti-PD-1 Inhibitor), Apatinib (VEGFR2 Inhibitor) and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer The study was designed…
- Trial name
- NCT04182724
- Testing
- Camrelizumab, Apatinib and Nab-paclitaxel
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Chinese PLA General Hospital
Metastasis Colorectal Cancer
Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer
This study is a single center, investigator initiated phase II clinical study to evaluate the efficacy and safety of fruquintinib plus Sintilimab as third-line therapy for colorectal cancer
- Trial name
- NCT04179084
- Testing
- fruquintinib, Sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Multiple Myeloma
Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma
This is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy and safety of BCMA-PD1-CART cells therapy for patients with relapsed/refractory Multiple Myeloma.
- Trial name
- NCT04162119
- Testing
- BCMA-PD1-CART Cell
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Lymphoma, B-Cell
Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma
This is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy and safety of CD19-PD1-CART cells therapy for patients with relapsed/refractory B Cell Lymphoma.
- Trial name
- NCT04163302
- Testing
- CD19-PD1-CART Cell
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Neuromyelitis Optica Spectrum Disorder
Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20
CAR-T therapy was proposed and has been recently used for cancer treatment. It has been hailed for its promising remission rates after early stage clinical trials for acute lymphoblastic leukemia.
- Trial name
- NCT03605238
- Testing
- Corticosteroids & tanCART19/20
- Where
- China
- Sponsor
- Chinese PLA General Hospital
Solid Tumor, Lymphoma
A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas
Identification of T cell inhibitory signals, including PD-1/PD-L1, has prompted the development of a new class of cancer immunotherapy that could restore an adequate immunosurveillance against the neoplasm and enhance…
- Trial name
- NCT03991559
- Testing
- Manganese Chloride, Anti-PD-1 antibody, Systemic therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese PLA General Hospital
Biliary Tract Cancer (BTC)
A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC
Biliary tract cancer (BTC) is a rare heterogeneous collection of malignancies arising within the biliary tract, characterized by innate chemoresistance and abysmal prognosis.
- Trial name
- NCT04004234
- Testing
- Manganese Chloride, nab-paclitaxel, Gemcitabine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese PLA General Hospital